Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK agrees another Zantac settlement in California
03:39am, Thursday, 01'st Feb 2024
GSK PLC (LSE:GSK, NYSE:GSK) has reached a confidential settlement regarding a lawsuit in California, which accused its discontinued heartburn medication, Zantac, of causing cancer, thus avoiding a tri
GSK confidentially settles another Zantac lawsuit in California
02:11am, Thursday, 01'st Feb 2024
GSK said on Thursday it agreed to confidentially settle one more lawsuit in California that alleged its discontinued heartburn drug Zantac caused cancer, the latest in a series of settlements to end c
GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance
01:16pm, Wednesday, 31'st Jan 2024
GSK's revenues benefit from strong growth across all segments, especially the Shingles and RSV vaccines. The company also issues fresh 2024 guidance for all its segments.
GSK posts blowout RSV vaccine sales, raises outlook as shots give big pharma a boost
09:47am, Wednesday, 31'st Jan 2024
The RSV shot, called Abrysvo, booked £1.2 billion, or $1.5 billion, in sales after only being on the market for roughly half a year.
GSK (GSK) Misses Q4 Earnings Estimates
08:06am, Wednesday, 31'st Jan 2024
GSK (GSK) came out with quarterly earnings of $0.72 per share, missing the Zacks Consensus Estimate of $0.76 per share. This compares to earnings of $0.64 per share a year ago.
GSK lifts long-term outlook following launch of blockbuster vaccine in 2023
07:08am, Wednesday, 31'st Jan 2024
GSK on Wednesday lifted its long-term outlook for 2026-2031 as it predicted new drug and vaccine launches will see its annual sales hit £38 billion by the start of the next decade following the block
GSK raises sales outlook to 2031 ahead of 12 major product launches
02:35am, Wednesday, 31'st Jan 2024
GSK PLC (LSE:GSK, NYSE:GSK) on Wednesday increased its outlook for sales out to 2031 driven by a raft of major product launches from 2025. Chief Executive Emma Walmsley said: “We are now planning fo
GSK's fourth-quarter results beat market estimate, sees 2024 growth
02:13am, Wednesday, 31'st Jan 2024
GSK beat market estimates for fourth-quarter profit and sales on Wednesday, underpinned by a strong launch of its respiratory syncytial virus (RSV) vaccine Arexvy and steady demand for its shingles sh
GSK Reports Earnings Wednesday. Watch the RSV Vaccine Showdown.
05:30pm, Tuesday, 30'th Jan 2024
The U.K.-based company is looking to recover after a lackluster 2023.
3 Hidden Healthcare Stocks Poised for a Breakout This Year
12:31pm, Tuesday, 30'th Jan 2024
One of the most important sectors not only in the financial markets but also in everyone's life, is the healthcare sector. It can provide investors with good returns due to its constant growth and con
Is a Surprise Coming for GSK This Earnings Season?
09:36am, Tuesday, 30'th Jan 2024
GSK is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
GSK Gears Up for Q4 Earnings: Will It Surpass Estimates?
12:56pm, Monday, 29'th Jan 2024
We expect GSK's specialty products like Arexvy, Cabenuva, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive fourth-quarter sales performance.
GSK RSV vaccine achieves blockbuster status in just over six months
10:47am, Monday, 29'th Jan 2024
GSK PLC has seen its RSV vaccines shoot to blockbuster status in little over six months, according to the Financial Times citing analysts. The term blockbuster refers to any drug with annual sales of
The Cutting Edge: 3 Stocks to Buy for the Next Generation of Biotech Breakthroughs
01:06pm, Thursday, 25'th Jan 2024
Integrating artificial intelligence and biotechnology could make 2024 a landmark year. The utilization of AI, machine learning and big data is nowadays a part of research and development (R&D) procedu
Why GSK (GSK) is a Top Value Stock for the Long-Term
10:41am, Thursday, 25'th Jan 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
